<DOC>
	<DOCNO>NCT02707601</DOCNO>
	<brief_summary>This study evaluate efficacy Ledipasvir/Sofosbuvir ( LDV/SOF ) measure proportion participant achieve hepatitis C virus ( HCV ) RNA low limit quantification ( LLOQ ) 12 week last dose LDV/SOF ( sustain virologic response ( SVR ) 12 ) . This study consist 2 part . In Part 1 , participant randomize switch stable antiretroviral ( ARV ) therapy either E/C/F/TAF F/R/TAF . The participant maintain HIV-1 RNA &lt; 50 copies/mL tolerate E/C/F/TAF F/R/TAF Part 1 continue Part 2 receive LDV/SOF treatment .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Ledipasvir/Sofosbuvir ( LDV/SOF ) Treatment HIV/HCV Co-infected Participants Who Switch Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( E/C/F/TAF ) Emtricitabine/Rilpivirine/Tenofovir Alafenamide ( F/R/TAF ) Prior LDV/SOF HCV Treatment</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Chronic genotype ( GT ) 1 , HCV infect , male nonpregnant/ nonlactating female individual , without cirrhosis , treatmentnaive treatmentexperienced interferon ( IFN ) +/ ribavirin ( RBV ) +/ HCV protease inhibitor ( PI ) . Compensated cirrhotic individual must HCV treatmentnaive . No prior treatment NS5A NS5B HCV direct acting antiviral , except boceprevir , telaprevir simeprevir , combination IFN RBV Currently ARV regimen ( 2 NRTI + third agent ) without change 6 month prior screen . Documented plasma HIV1 RNA level &lt; 50 copies/mL ( undetectable HIV1 RNA level accord local assay use limit detection ≥ 50 copies/mL ) ≥ 6 month precede screen visit . After reach HIV1 RNA &lt; 50 copies/mL , single value ( `` blip '' ) HIV1 RNA ≥ 50 copies/mL follow resuppression allow . For individual 3 prior ARV regimen , regimen history provide approval Sponsor . Note : Individuals change TDF TAF le 6 month ago eligible long TDF/ TAF change change regimen . Plasma HIV1 RNA level &lt; 50 copies/mL screen visit Have document resistance HIV study agent time past , include limited reverse transcriptase resistance mutation K65R , K70E , K101E/P , E138A/G/K/R/Q , V179L , Y181C/I/V , M184V/I , Y188L , H221Y , F227C , M230I/L , combination K103N+L100I , 3 thymidine analog associate mutation ( TAMs ) include M41L L210W ( TAMs M41L , D67N , K70R , L210W , T215Y/F , K219Q/E/N/R ) . If historical genotype prior first ARV available individual 3 prior ARV regimen , individual proviral genotype analysis archive resistance prior Day 1 . No history HIV virologic failure No evidence Hepatitis B infection Estimated glomerular filtration rate ( eGFR ) ≥ 30 mL/min estimate CockcroftGault formula NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HCV direct act antiviral ( ) ( DAA )</keyword>
</DOC>